2021 Good Quality Capecitabine - Olaparib AZD-2281 CAS 763113-22-0 Purity ≥99.0% API Factory – Ruifu

Short Description:

Product Detail

Product Tags

Feedback (2)

We have been proud from the higher consumer gratification and wide acceptance due to our persistent pursuit of high quality both on product or service and service for Bedaquiline Fumarate, Molecular Formula C9H10O3, Molecular Formula C21H21N3O5, Welcome any inquiry to our company. We will be glad to establish friendly business relationships with you!

2021 Good Quality Capecitabine - Olaparib AZD-2281 CAS 763113-22-0 Purity ≥99.0% API Factory – Ruifu Detail:

Supply With High Purity, Commercial Production

Chemical Name	Olaparib
Synonyms	AZD-2281; KU0059436; Lynparza; 4-(3-(4-(cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)Methyl]-2-fluorobenzoyl]piperazin
CAS Number	763113-22-0
CAT Number	RF-API103
Stock Status	In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula	C24H23FN4O3
Molecular Weight	434.46
Solubility	Soluble in DMSO
Brand	Ruifu Chemical

Item	Specifications
Appearance	White to Off-White Powder
Identification by 1H NMR	Comply with the structure
LC-MS	Comply with the structure
Purity / Analysis Method	≥99.0% (by LC-MS)
Moisture (K.F)	≤0.50%
Single Impurity	≤0.50%
Total Impurities	≤1.0%
Heavy Metals (as Pb)	≤20ppm
Test Standard	Enterprise Standard
Usage	API; PARP Inhibitor

Package: Bottle, Aluminium foil bag, Cardboard Drum, 25kg/Drum, or according to customer’s requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Olaparib (CAS: 763113-22-0), a highly potent and selective PARP-inhibitor. In December 19, 2014, the FDA approved novel anti-cancer drug Olaparib (Lynparza) for monotherapy to the patients of advanced ovarian cancer who has undergone at least 3 rounds of chemotherapy or patients of suspected BRCA mutations. At the same time, FDA approved the quantitation and classification of diagnostic kits for the detection of mutations in BRCA1 and BRCA2, BRACAnalysis CDx. Olaparib is the first PARP inhibitor drugs which has been approved by FDA. In February 2, 2015, the European Union Food and Drug Administration (EMA) also approved Olaparib to enter into market in the 28 countries of European Union including Iceland, Liechtenstein and Norway. But the indications of EMA and FDA approved are slightly different; the former is for the BRCA gene mutation cases, and also for the maintenance therapy for patients of advanced epithelial ovarian cancer who has previously received platinum-containing chemotherapy drugs and exhibit response and subject to recurrence.

Product detail pictures:

Related Product Guide:

We'll make every effort and hard work to be superb and excellent, and speed up our steps for standing inside the rank of intercontinental top-grade and high-tech enterprises for 2021 Good Quality Capecitabine - Olaparib AZD-2281 CAS 763113-22-0 Purity ≥99.0% API Factory – Ruifu , The product will supply to all over the world, such as: Slovak Republic, Nairobi, Vancouver, Looking forward, we will keep pace with the times, continuing to create new products. With our strong research team, advanced production facilities, scientific management and top services, we will supply high quality products to our customers worldwide. We sincerely invite you to be our business partners for mutual benefits.